Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory

Fig. 4

Dose-dependent GITRL-FP expansion of antigen-specific T cells. a CT26 tumor–bearing mice were treated with a single dose of GITRL-FP had no detectable tumors and were protected from rechallenge on day 85 (R arrow). b On day 120 after rechallenge with CT26, mouse spleens were harvested (PD arrow), processed to single-cell suspensions, and restimulated with 10 μg/mL AH1 peptide/protein transport inhibitor for 5 h. A dose-dependent increase was observed in AH1-specific T cells. c Representative plot of 5 mice from each group. For comparison, data from naïve mice and untreated mice with CT26 tumors at day 10 are shown

Back to article page